Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

This study is currently recruiting participants.

Verified by Shaheed Beheshti Medical University, November 2006

First Received: August 30, 2006 Last Updated: November 13, 2006 History of Changes

Sponsor:	Shaheed Beheshti Medical University
Information provided by:	Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:	NCT00370539

Purpose

To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.

Condition	Intervention	Phase
Neovascular Age-Related Macular Degeneration	Drug: verteporfin, bevacizumab, triamcinolone acetonide	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Triamcinolone diacetate Triamcinolone acetonide Verteporfin Bevacizumab Triamcinolone Triamcinolone hexacetonide

U.S. FDA Resources

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:

Visual acuity

Secondary Outcome Measures:

Central macular thickness
Leakage in fluorescein angiography
Intraocular pressure
Anterior chamber reaction

Study Start Date:	September 2006
Estimated Study Completion Date:	November 2006

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria:

History of glaucoma or ocular hypertension
Disciform scar

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370539

Contacts

Contact: Hamid Ahmadieh, MD

+98 21 22585952

hahmadieh@hotmail.com

Locations

Iran, Islamic Republic of
Hamid Ahmadieh, MD	Recruiting
Tehran, Iran, Islamic Republic of, 16666
Contact: Hamid Ahmadieh, MD +98 21 22585952 hahmadieh@hotmail.com

Sponsors and Collaborators

Shaheed Beheshti Medical University

Investigators

Principal Investigator:

Hamid Ahmadieh, MD

Ophthalmic Research Center of Shaheed Beheshti Medical University

More Information

No publications provided

Study ID Numbers:	8542
Study First Received:	August 30, 2006
Last Updated:	November 13, 2006
ClinicalTrials.gov Identifier:	NCT00370539 History of Changes
Health Authority:	Iran: Ethics Committee

Keywords provided by Shaheed Beheshti Medical University:

Photodynamic therapy,
Bevacizumab,
Triamcinolone,
Age-related macular degeneration,
Choroidal neovascular membrane

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Bevacizumab
Hormones
Triamcinolone hexacetonide
Triamcinolone Acetonide
Therapeutic Uses
Triamcinolone
Growth Inhibitors
Angiogenesis Modulating Agents
Dermatologic Agents

Retinal Diseases
Growth Substances
Eye Diseases
Verteporfin
Retinal Degeneration
Macular Degeneration
Triamcinolone diacetate
Enzyme Inhibitors
Glucocorticoids
Immunosuppressive Agents
Angiogenesis Inhibitors
Pharmacologic Actions
Photosensitizing Agents
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on February 08, 2010